Therini Bio
therinibio.com
Actively hiring
Professional Services
Health Care
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$260.5M
7 rounds on record
Latest round
$39M
Series A · May 2025 · 16 mo ago
Team
4
US Form 5500 (plan participants) · Dec 2025 · -20% in a year
Backers
1
Angelini Ventures
The money's age
Due for its next round
16 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 14, 2025
Raised a round Series A $39M
Apr 26, 2023
Raised a round Series A $36M
May 10, 2021
Raised a round Seed $17M
May 8, 2019
Raised a round Venture round $9.4M · SEC Form D
May 8, 2019
Raised a round Venture round $9.4M · SEC Form D
2016
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | May 2025 | $39M | — | therinibio.com |
| Series A | Apr 2023 | $36M | — | businesswire.com |
| Venture round | Mar 2023 | $74.9M | — | SEC Form D |
| Venture round | Mar 2023 | $74.9M | — | SEC Form D |
| Seed | May 2021 | $17M | — | therinibio.com |
| Venture round | May 2019 | $9.4M | — | SEC Form D |
| Venture round | May 2019 | $9.4M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Therini Bio, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Leslie SchulzeExecutive OfficerSEC Form D
Jeffrey Stavenhagen Ph.D.Executive OfficerSEC Form D
Daniel BurgessDirectorSEC Form D
Jeffrey StavenhagenExecutive OfficerSEC Form D
Michael QuigleyExecutive Officer, DirectorSEC Form D
Tara NickersonExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Angelini Ventures Similar startupsby what they do, their industry and backers
Driving immune-mediated therapeutic innovation for women. Freya focuses on the underlying drivers of disease, not just symptoms.
Innovative technology for life-changing care At Noctrix Health, Inc. we are developing the next generation of clinically validated wearable…
Argobio SAS is a newly-created START-UP STUDIO dedicated to novel Therapeutics aiming to nurture and launch at least five breakthrough…
Trotana is developing novel oral anti-inflammatory medicines.
At Pheast Therapeutics, we are developing new innate immune checkpoint inhibitors, including anti-CD24, to unleash the power of macrophages…
By harnessing the potential of the innate immune system, we are developing ground breaking NK cell and small molecule therapies. Learn More…
News
Therini Bio Doses First Patients in Phase 1b Trial of Novel Anti-Inflammatory Therapy, THN391, for Diabetic Macular Edema
- Company also advances fibrin/VEGF bispecific antibody THN622, a potential new standard of care for retinal neurodegeneration Sacramento, May 27, 2026 (GLOBE NEWSWIRE) - Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immu
Read more
Report
Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer's Disease
- Pioneering approach to halting the chronic neuroinflammation responsible for neurodegeneration- Trial to assess safety, PK and detect early signs of efficacy- Initial data expected in mid-2026 SACRAMENTO, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Therin
Read more
Report
Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer's Disease
- Pioneering approach to halting the chronic neuroinflammation responsible for neurodegeneration- Trial to assess safety, PK and detect early signs of efficacy- Initial data expected in mid-2026 Sacramento, July 29, 2025 (GLOBE NEWSWIRE) - Therini Bio, In
Read more
Report
Therini Bio: $39 Million Series A Secured For Advancing Clinical Development Of Neurodegenerative Disease Immunotherapies
Therini Bio - a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction - announced that it raised $39 million in a Series A extension financing. This extension financing inc
Read more
Report
Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline
Read more
Report
Therini Bio Announces Positive Phase 1a Trial Results Evaluating THN391 for Neurodegenerative Diseases
- Novel approach to treat neurodegenerative diseases by targeting fibrin-driven neuroinflammation was well-tolerated among healthy volunteers, with a clean hematological profile- Half-life supports once-monthly dosing- Data to be presented at AAIC 25 Sacr
Read more
Report
Therini Bio Announces Positive Phase 1A Trial Results Evaluating THN391 For Neurodegenerative Diseases
Read more
Report
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases
- THN391 demonstrated effectiveness in protecting against vascular and neuronal degeneration- Therini Bio plans to initiate a Phase 1/2a trial evaluating THN391 in DME in 2H24- The data was presented at ARVO 2024 Sacramento, May 8, 2024 (GLOBE NEWSWIRE) -
Read more
Report
Therini Bio Announces Interim Results from the Phase 1 Trial of THN391 for the Potential Treatment of Dementia
- THN391 was found to be safe and well-tolerated- THN391 demonstrated a prolonged half-life and dose proportional Cmax levels- The data will be presented October 25-27th at CTAD 2023 Sacramento, October 24, 2023 (GLOBE NEWSWIRE) - Therini Bio, Inc., a bio
Read more
Report
Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer's Disease
- Industry Veteran Frank D. Lee Appointed as Executive Chairperson of the Board SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)- Therini Bio, Inc., a biotech company focused on developing fibrin targeted therapies to treat inflammatory neurodegenerative and r
Read more
Report
Show more news
People
Leslie Schulze
Executive Officer
Jeffrey Stavenhagen Ph.D.
Executive Officer
Daniel Burgess
Director
Jeffrey Stavenhagen
Executive Officer
Michael Quigley
Executive Officer, Director
Tara Nickerson
Executive Officer, Director
Edward Spack
Executive Officer
Aikaterini Akasoglou
Director
Laurence Barker
Director
Tracy Saxton
Director
Michael Ross
Director
Houman Ashrafian
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
South San Francisco
United States
HQ
Sacramento
United States
Regional office
Connect with Us
2108 N ST, STE.# 4963, Sacramento, CA 95816
Financials
Total raised
$260.5M
Latest round
Series A
Funding rounds
7